Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



King's College London - Health: More than a medical matter





Roche withdraws bid for DNA sequencing pioneer Illumina

30 April 2012

By Ruth Saunders

Appeared in BioNews 654

The standoff between Roche and Illumina, which provides services and equipment for genetic analysis, finally came to an end last week as the Swiss pharmaceuticals giant ended efforts for a hostile takeover bid.

Roche began proceedings earlier this year (reported in BioNews 642) to acquire all outstanding shares of Illumina, later increasing its offer from $5.7 billion to $6.8 billion.

The announcement came after Illumina's shareholders voted to re-elect all of Illumina's directors to the board at the company's annual meeting. It follows attempts by Roche to install board members favourable to the takeover, in order to force Illumina to the negotiating table.

'We have throughout this process desired to engage in a constructive dialogue with Illumina's management, listen to its views of value and prospects, and offer a fair and adequate price to Illumina's shareholders', said Severin Schwan, CEO of Roche. 'But in the absence of such discussions, our duty to be disciplined with the assets of Roche's shareholders has led to this decision'.

Illumina, on the other hand, felt that the takeover proposals were priced too low.

'We are pleased that Roche has decided not to extend its inadequate offer to acquire Illumina and that we can now return our full focus to growing our business', Jay Flatley, CEO of Illumina, said.

Roche's refusal to push its hostile takeover bid may reflect the uncertainty of its investors that Illumina will win the race to introduce the fastest,cheapest gene sequencing technology.

It faces stiff competition from Nanopore, based in Oxford in the UK, who announced the development of a powerful sequencing platform set for commercial release later this year, and global biotechnology giant Life Technologies.

Illumina has countered such conjecture, stating that it expects high demand for its new products which will be faster and more accurate than other offerings on the market.

'A lot of people in the sequencing industry really don't know which technology is going to win in the end', Jack Scannell from investment management firm Sanford C. Bernstein told Bloomberg. 'That spooked a lot of Roche shareholders. There is a huge amount of caution that you end up buying Betamax and not VHS'.

The future remains uncertain. 'I don't think Roche has completely given up', Bryan Brokmeier from investment bankers Maxim Group told Bloomberg. 'They may come back with an offer if Illumina shares don't move or if Illumina comes out with better news on its pipeline'.

 

SOURCES & REFERENCES
Illumina (press release) | 18 April 2012
 
DealBook (New York Times) | 18 April 2012
 
Nature News Blog | 18 April 2012
 
Roche (press release) | 18 April 2012
 
Bloomberg | 19 April 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

17 June 2013 - by Jessica Ware 
The first IVF business to be listed on the stock market enjoyed a buoyant first day of trading on the Australian exchange. Shares in Virtus Health closed 8.5 percent above their starting price, which was already set at the top end of an indicative range... [Read More]
17 December 2012 - by Holly Rogers 
The US biotechnology company Amgen will buy deCODE Genetics, which provides products and services for genome analysis, for $415 million... [Read More]
16 July 2012 - by Daryl Ramai 
Technology that relies on less DNA to more accurately sequence people's genomes has been unveiled by a US biotech company... [Read More]

31 January 2012 - by Ruth Saunders 
Swiss pharmaceutical company Roche has made an unsolicited bid worth $5.7 billion to takeover US DNA sequencing firm Illumina.... [Read More]
16 January 2012 - by Dr Zara Mahmoud 
A US biotechnology firm has unveiled an automated desktop DNA sequencer that can decode the sequence of the human genome in one day for as little as $1,000 (£650). Given its first public viewing at a consumer electronics show in Las Vegas, Life Technologies Corporation's Ion Proton sequencer uses microchips similar to those found in digital cameras... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to Login or Register to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
RISK ASSESSMENT:
BREAST CANCER, PREDICTION AND SCREENING
FREE public event in central London, 6.30pm on Thursday 8 May 2014 - find out more HERE

DataLabel Supplying Printed Labels To The UK For Over 15 Years

ANNIVERSARY APPEAL
Please donate HERE, so that the Progress Educational Trust can continue throughout 2014 (and beyond) while keeping BioNews FREE for you to read

The Progress Educational Trust was shortlisted for the Charity Times Awards 2011

Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE, and give the Progress Educational Trust a regular donation